Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy
AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and...
Gespeichert in:
Veröffentlicht in: | British journal of ophthalmology 2021-06, Vol.105 (6), p.844-849 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 849 |
---|---|
container_issue | 6 |
container_start_page | 844 |
container_title | British journal of ophthalmology |
container_volume | 105 |
creator | Park, Dong-Geun Jeong, Seongyong Noh, Donghyoun Sagong, Min |
description | AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863. |
doi_str_mv | 10.1136/bjophthalmol-2020-316837 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429058265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2529679785</sourcerecordid><originalsourceid>FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</originalsourceid><addsrcrecordid>eNqNkD1PwzAURS0EoqXwF1AkFpaAP2o7GVHFl1SpCwxMluM8K6mSONjO0H-PqxaEmJisd3Xu89NBKCP4jhAm7qutG5vY6K53XU4xxTkjomDyBM3JUhQpkuUpmmOMZU6IIDN0EcI2jVQQeY5mjEoqJWNz9LEZY9vrLrPdBIOBzOsImbPZ2Ljo6t2g-9ZksQGvx11mnc9M492QMgND9KkYwLsppNj51nmI7eBGHZvdJTqzugtwdXwX6P3p8W31kq83z6-rh3VesULGvJCYghW45tLURDAiQVTM8nJZ1aauuMDcQmlAc2sMB6hLgZnUxFa4JlRYtkC3h72jd58ThKj6NhjoOj1AOkzRJS0xL6jgCb35g27d5Id0naKclkKWsthTxYEy3oXgwarRJ0V-pwhWe_3qt361168O-lP1-vjBVPVQ_xS_fSeAHYCq3_5_7Rdw-peJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2529679785</pqid></control><display><type>article</type><title>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</title><source>PubMed Central (PMC)</source><creator>Park, Dong-Geun ; Jeong, Seongyong ; Noh, Donghyoun ; Sagong, Min</creator><creatorcontrib>Park, Dong-Geun ; Jeong, Seongyong ; Noh, Donghyoun ; Sagong, Min</creatorcontrib><description>AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2020-316837</identifier><identifier>PMID: 32727733</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Demographics ; Eye diseases ; Ischemia ; Medical imaging ; Photodynamic therapy ; Photoreceptors ; Vascular endothelial growth factor</subject><ispartof>British journal of ophthalmology, 2021-06, Vol.105 (6), p.844-849</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</citedby><cites>FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</cites><orcidid>0000-0003-4140-5015 ; 0000-0001-9175-9642</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32727733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Dong-Geun</creatorcontrib><creatorcontrib>Jeong, Seongyong</creatorcontrib><creatorcontrib>Noh, Donghyoun</creatorcontrib><creatorcontrib>Sagong, Min</creatorcontrib><title>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.</description><subject>Demographics</subject><subject>Eye diseases</subject><subject>Ischemia</subject><subject>Medical imaging</subject><subject>Photodynamic therapy</subject><subject>Photoreceptors</subject><subject>Vascular endothelial growth factor</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkD1PwzAURS0EoqXwF1AkFpaAP2o7GVHFl1SpCwxMluM8K6mSONjO0H-PqxaEmJisd3Xu89NBKCP4jhAm7qutG5vY6K53XU4xxTkjomDyBM3JUhQpkuUpmmOMZU6IIDN0EcI2jVQQeY5mjEoqJWNz9LEZY9vrLrPdBIOBzOsImbPZ2Ljo6t2g-9ZksQGvx11mnc9M492QMgND9KkYwLsppNj51nmI7eBGHZvdJTqzugtwdXwX6P3p8W31kq83z6-rh3VesULGvJCYghW45tLURDAiQVTM8nJZ1aauuMDcQmlAc2sMB6hLgZnUxFa4JlRYtkC3h72jd58ThKj6NhjoOj1AOkzRJS0xL6jgCb35g27d5Id0naKclkKWsthTxYEy3oXgwarRJ0V-pwhWe_3qt361168O-lP1-vjBVPVQ_xS_fSeAHYCq3_5_7Rdw-peJ</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Park, Dong-Geun</creator><creator>Jeong, Seongyong</creator><creator>Noh, Donghyoun</creator><creator>Sagong, Min</creator><general>BMJ Publishing Group LTD</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4140-5015</orcidid><orcidid>https://orcid.org/0000-0001-9175-9642</orcidid></search><sort><creationdate>202106</creationdate><title>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</title><author>Park, Dong-Geun ; Jeong, Seongyong ; Noh, Donghyoun ; Sagong, Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Demographics</topic><topic>Eye diseases</topic><topic>Ischemia</topic><topic>Medical imaging</topic><topic>Photodynamic therapy</topic><topic>Photoreceptors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Dong-Geun</creatorcontrib><creatorcontrib>Jeong, Seongyong</creatorcontrib><creatorcontrib>Noh, Donghyoun</creatorcontrib><creatorcontrib>Sagong, Min</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Dong-Geun</au><au>Jeong, Seongyong</au><au>Noh, Donghyoun</au><au>Sagong, Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2021-06</date><risdate>2021</risdate><volume>105</volume><issue>6</issue><spage>844</spage><epage>849</epage><pages>844-849</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><abstract>AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>32727733</pmid><doi>10.1136/bjophthalmol-2020-316837</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4140-5015</orcidid><orcidid>https://orcid.org/0000-0001-9175-9642</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1161 |
ispartof | British journal of ophthalmology, 2021-06, Vol.105 (6), p.844-849 |
issn | 0007-1161 1468-2079 |
language | eng |
recordid | cdi_proquest_miscellaneous_2429058265 |
source | PubMed Central (PMC) |
subjects | Demographics Eye diseases Ischemia Medical imaging Photodynamic therapy Photoreceptors Vascular endothelial growth factor |
title | Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T14%3A25%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20fluence%20rate%20of%20photodynamic%20therapy%20for%20chronic%20central%20serous%20chorioretinopathy&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Park,%20Dong-Geun&rft.date=2021-06&rft.volume=105&rft.issue=6&rft.spage=844&rft.epage=849&rft.pages=844-849&rft.issn=0007-1161&rft.eissn=1468-2079&rft_id=info:doi/10.1136/bjophthalmol-2020-316837&rft_dat=%3Cproquest_cross%3E2529679785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2529679785&rft_id=info:pmid/32727733&rfr_iscdi=true |